Shots:
- The P-Ib/II CodeBreaK 101 study evaluates Lumakras + Vectibix in 31 patients with KRAS G12C-mutated advanced CRC
- The results demonstrated ORR (27%) among 26 patients in the efficacy analysis, DCR (81%), 33% of patients experienced a response in the expansion cohort, no patients experienced dose-limiting toxicities during the 28 days following initial treatment. The therapy also demonstrated the efficacy and safety
- Amgen has completed an enrolment in P-III CodeBreaK 200 trial to evaluate sotorasib vs docetaxel in patients with KRAS G12C-mutated NSCLC. Lumakras is also being studied in multiple other solid tumors
Click here to read full press release/ article | Ref: PR Newswire | Image: Wall Street Journal
The post Amgen Presents Results of Lumakras (sotorasib) + Vectibix (panitumumab) in P-Ib/II CodeBreaK 101 study for KRAS G12C-Mutated Colorectal Cancer at ESMO21 2021 first appeared on PharmaShots.
